Search results for "Stage"

showing 10 items of 1393 documents

Prognostic scoring system predictive of survival after surgical resection of esophageal carcinoma.

2013

BACKGROUND The aim of our study was to develop a prognostic index score for patients undergoing surgical resection for esophageal cancer that accurately determines survival with specific clinicopathological characteristics. METHODS Clinical, histological, and demographical variables of 475 patients were entered in an univariate and multivariate regression model, followed by individual calculation of the Prognostic Indicator Score and model validation via simulation. RESULTS Significant variables included in the scoring system were number of positive lymph nodes, pT, pL, R, obesity, and American Society of Anesthesiologist classification. Survival probability and its associated hazard functi…

Pulmonary and Respiratory MedicineOncologyAdultMalemedicine.medical_specialtyEsophageal NeoplasmsKaplan-Meier EstimateAdenocarcinomaRisk AssessmentDecision Support TechniquesPostoperative ComplicationsRisk FactorsStatistical significanceInternal medicineCarcinomaMedicineHumansComputer SimulationStage (cooking)AgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesAged 80 and overbusiness.industryPatient SelectionHazard ratioUnivariateCancerReproducibility of ResultsEsophageal cancerMiddle Agedmedicine.diseaseEsophagectomyTreatment OutcomeMultivariate AnalysisCarcinoma Squamous CellAdenocarcinomaSurgeryFemaleCardiology and Cardiovascular MedicinebusinessThe Thoracic and cardiovascular surgeon
researchProduct

Long-term survival after lobectomy and pneumonectomy in patients with stage II non-small cell lung cancer (NSCLC)

2012

Pulmonary and Respiratory MedicineOncologyCancer Researchmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentStage II Non-Small Cell Lung CancerPneumonectomyOncologyInternal medicineLong term survivalMedicineIn patientbusinessLung Cancer
researchProduct

Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer--what limits l…

2002

Small cell lung cancer (SCLC) is usually classified into a two-stage system, limited (LD) and extensive disease (ED). However, the criteria for these two categories remain controversial. The widely used Veterans Administration Lung Study Group (VALG) definition of LD includes patients with primary tumor and nodal involvement limited to one hemithorax. In contrast, the International Association for the Study of Lung Cancer (IASLC) recommends that LD should additionally include all patients without distant metastasis. As a consequence, since treatment modalities for LD and ED could be different, individual clinical outcome of SCLC patients may be influenced by the staging system chosen. Among…

Pulmonary and Respiratory MedicineOncologyMaleCancer Researchmedicine.medical_specialtyLung NeoplasmsSurvivalPopulationInternal medicinemedicineCarcinomaHumansLongitudinal StudiesStage (cooking)Carcinoma Small CelleducationLung cancerAgedNeoplasm StagingVeteranseducation.field_of_studybusiness.industryProportional hazards modelRespiratory diseaseHazard ratioMiddle Agedmedicine.diseasePrognosisPrimary tumorSurgeryOncologyRegression AnalysisFemalebusinessLung cancer (Amsterdam, Netherlands)
researchProduct

P-147PLASMA PLATELET FACTOR 4 AS PREDICTOR OF ANGIOGENIC ACTIVITY: DIAGNOSTIC AND PROGNOSTIC TOOL FOR EARLY STAGE NON-SMALL CELL LUNG CANCER

2013

Pulmonary and Respiratory MedicineOncologymedicine.medical_specialtyAngiogenesisbusiness.industryCancermedicine.diseaseInternal medicinemedicineAdjuvant therapyAdenocarcinomaSurgeryStage (cooking)Cardiology and Cardiovascular MedicineLung cancerbusinessSurvival ratePlatelet factor 4Interactive CardioVascular and Thoracic Surgery
researchProduct

P48.10 Chemo-Immunotherapy in the Frontline of Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Indirect Comparisons

2021

Pulmonary and Respiratory MedicineOncologymedicine.medical_specialtyOncologybusiness.industryInternal medicineMedicinebusinessExtensive-stage small cell lung cancerChemo immunotherapyJournal of Thoracic Oncology
researchProduct

Outcomes of Patients With Advanced NSCLC From the Intergroupe Francophone de Cancérologie Thoracique Biomarkers France Study by KRAS Mutation Subtypes

2020

Abstract Introduction KRAS mutations are detected in 20% to 30% of NSCLC. However, KRAS mutation subtypes may differently influence the outcome of patients with advanced NSCLC. Methods In the Biomarkers France study, 4894 KRAS mutations (26.2%) were detected in 4634 patients from the 17,664 enrolled patients with NSCLC. Survival and treatment data on noncurative stage III to IV NSCLC were available for 901 patients. First- and second-line treatment effects on progression-free survival and overall survival were analyzed according to the KRAS mutations subtype. Results Over 95% of patients with KRAS mutation were smokers or former smokers who were white (99.5%), presenting with adenocarcinoma…

Pulmonary and Respiratory MedicineOncologymedicine.medical_specialtyendocrine system diseases[SDV.CAN]Life Sciences [q-bio]/Cancermedicine.disease_causeNSCLClcsh:RC254-28203 medical and health sciences0302 clinical medicine[SDV.CAN] Life Sciences [q-bio]/CancerNon-small cell lung cancerInternal medicinemedicineOverall survivalNon–small cell lung cancerStage (cooking)neoplasms030304 developmental biology0303 health sciencesMutationTransition (genetics)business.industryKRAS mutationmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisConfidence intervaldigestive system diseases3. Good healthrespiratory tract diseasesOncology030220 oncology & carcinogenesisAdenocarcinomaOriginal ArticleKRASbusinessKras mutation
researchProduct

P121 Characteristics of COPD patients with and without maintenance treatment at baseline, by GOLD stage: TONADO: Abstract P121 Table 1

2015

Rationale The efficacy and safety of the once-daily combination of tiotropium (T), a long-acting muscarinic antagonist (LAMA), and olodaterol (O), a long-acting β 2 -agonist (LABA), for the treatment of chronic obstructive pulmonary disease (COPD) has been established. We investigated whether there was a difference in the characteristics of COPD patients with and without baseline maintenance treatment. Methods Two replicate, randomised, 52-week, double-blind, parallel-group, Phase III trials (NCT01431274; NCT01431287; n = 5162) assessed the efficacy and safety of once-daily treatment with T+O (2.5/5 μg; 5/5 μg; Respimat® inhaler) compared to the individual components. Baseline characteristi…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyCOPDbiologybusiness.industryInhalerOlodaterolMuscarinic antagonistLamabiology.organism_classificationmedicine.diseaseObstructive lung diseaseSurgeryPulmonary function testingchemistry.chemical_compoundchemistryInternal medicinemedicinebusinessGold stagemedicine.drugThorax
researchProduct

Multi-stage Linear Programming Optimization for Pump Scheduling

2014

This study presents a methodology based on Linear Programming for determining the optimal pump schedule on a 24-hour basis, considering as decision variables the continuous pump flow rates which are subsequently transformed into a discrete schedule. The methodology was applied on a case study derived from the benchmark Anytown network. To evaluate the LP reliability, a comparison was made with solutions generated by a Hybrid Discrete Dynamically Dimensioned Search (HD-DDS) algorithm. The cost associated with the result derived from the LP initial solution was shown to be lower than that obtained with repeated HD-DDS runs with differing random seeds. (C) 2013 The Authors. Published by Elsevi…

Pump schedulingOptimizationEngineeringMathematical optimizationLinear programmingbusiness.industryGeneral MedicineHD-DDSScheduling (computing)Pump flowMulti stageDecision variablesLinear ProgrammingbusinessEngineering(all)Procedia Engineering
researchProduct

Extreme nucleoside concentrations in a marine annelid: a novel nucleoside storing cell in the polychaete Nereis virens.

2010

A new type of free coelomic cell was isolated from the coelomic fluid of the polychaete Nereis virens. This cell type was present only during sexual maturation and only in males with fully developed spermatozoa. In vivo acridine orange staining and electron microscopy showed that this cell type consists mainly of a large acidic vacuole with a very low proportion of cytoplasm. This cell type stores extremely high concentration of purine nucleosides reaching concentrations of >700 millimolar on a cell weight basis. The nucleoside concentrations are the highest reported from any living cell so far. Inosine (280-711 micromol/g cell mass), guanosine (8-109 micromol/g), deoxyinosine (3-26 micromo…

PurineMalePhysiologyGuanosineVacuoleBiologyBiochemistrychemistry.chemical_compoundmedicineDeoxyguanosineAnimalsInosineMolecular BiologyLife Cycle StagesGuanosineNucleotidesAcridine orangeNucleosidesPolychaetaInosinechemistryBiochemistryCytoplasmVacuolesNucleosidemedicine.drugComparative biochemistry and physiology. Part B, Biochemistrymolecular biology
researchProduct

Impact de l'âge dans le cancer du sein : du diagnostic à la qualité de vie des patientes

2014

Numerous studies have shown that older women with breast cancer are undertreated in comparison with the youngest. Although several reports suggest strong socio-economic and geographic inequalities in the disease stage at diagnosis and in quality of life in breast cancer patients, the effects of these factors according to age are largely unknown in France. The objectives of this work were to determine the impact of socio-economic and geographic disparities on disease stage in breast cancer patients according to age, to describe treatments and relative survival factors in breast cancer patients according to age, and to identify age-related socioeconomic and clinical determinants of quality of…

Quality of life[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologySocio-economic inequalitiesSurvivalQualité de vieStage at diagnosisStade de diagnosticTraitementsTreatmentBreast cancerAgeSurvie[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyCancer du seinInégalités socio-économiques
researchProduct